MXPA05006272A - Novedosos antagonistas de receptores de mch. - Google Patents

Novedosos antagonistas de receptores de mch.

Info

Publication number
MXPA05006272A
MXPA05006272A MXPA05006272A MXPA05006272A MXPA05006272A MX PA05006272 A MXPA05006272 A MX PA05006272A MX PA05006272 A MXPA05006272 A MX PA05006272A MX PA05006272 A MXPA05006272 A MX PA05006272A MX PA05006272 A MXPA05006272 A MX PA05006272A
Authority
MX
Mexico
Prior art keywords
carboxylic acid
biphenyl
phenoxy
ethylsulfanylmethyl
amide
Prior art date
Application number
MXPA05006272A
Other languages
English (en)
Spanish (es)
Inventor
Michael Morin Junior John
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA05006272A publication Critical patent/MXPA05006272A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA05006272A 2002-12-11 2003-12-03 Novedosos antagonistas de receptores de mch. MXPA05006272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43270102P 2002-12-11 2002-12-11
PCT/US2003/037071 WO2004052848A1 (en) 2002-12-11 2003-12-03 Novel mch receptor antagonists

Publications (1)

Publication Number Publication Date
MXPA05006272A true MXPA05006272A (es) 2005-08-19

Family

ID=32507985

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006272A MXPA05006272A (es) 2002-12-11 2003-12-03 Novedosos antagonistas de receptores de mch.

Country Status (9)

Country Link
US (1) US7132456B2 (https=)
EP (1) EP1572637A1 (https=)
JP (1) JP2006509801A (https=)
CN (1) CN1726189A (https=)
AU (1) AU2003302925A1 (https=)
BR (1) BR0316948A (https=)
CA (1) CA2509042A1 (https=)
MX (1) MXPA05006272A (https=)
WO (1) WO2004052848A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329656B2 (en) 2004-10-08 2008-02-12 H. Lundbeck A/S Arylthiobenzylpiperidine derivatives
US7446204B2 (en) 2004-10-08 2008-11-04 H. Lundbeck A/S Amino substituted aryloxybenzylpiperidine derivatives
WO2006066174A1 (en) * 2004-12-17 2006-06-22 Eli Lilly And Company Thiazolopyridinone derivates as mch receptor antagonists
KR101356093B1 (ko) 2005-03-28 2014-01-27 가부시키가이샤 한도오따이 에네루기 켄큐쇼 안트라센 유도체, 발광소자용 재료, 발광소자, 발광장치 및전자기기
US7731377B2 (en) * 2006-03-21 2010-06-08 Semiconductor Energy Laboratory Co., Ltd. Backlight device and display device
US7772162B2 (en) 2006-03-27 2010-08-10 Board Of Regents, The University Of Texas System Use of fluorocarbon surfactants to improve the productivity of gas and gas condensate wells
US20070225176A1 (en) * 2006-03-27 2007-09-27 Pope Gary A Use of fluorocarbon surfactants to improve the productivity of gas and gas condensate wells
EP2418202B1 (en) 2006-03-31 2014-01-29 Novartis AG (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors
WO2008021849A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
CN101506163B (zh) * 2006-08-30 2012-05-02 株式会社半导体能源研究所 合成蒽衍生物的方法和蒽衍生物、发光元件、发光装置、电子装置
US9353309B2 (en) * 2007-03-23 2016-05-31 Board Of Regents, The University Of Texas System Method for treating a formation with a solvent
US7723722B2 (en) 2007-03-23 2010-05-25 Semiconductor Energy Laboratory Co., Ltd. Organic compound, anthracene derivative, and light-emitting element, light-emitting device, and electronic device using anthracene derivative
RU2453690C2 (ru) * 2007-03-23 2012-06-20 Борд Оф Риджентс, Зе Юниверсити Оф Техас Систем Способ обработки углеводородной формации
US20080286445A1 (en) * 2007-05-17 2008-11-20 Semiconductor Energy Laboratory Co., Ltd. Composition, and method of fabricating light-emitting element
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
AU2008331558A1 (en) * 2007-11-30 2009-06-11 3M Innovative Properties Company Methods for improving the productivity of oil producing wells
CN102089282A (zh) * 2008-07-08 2011-06-08 株式会社半导体能源研究所 咔唑衍生物、发光元件用材料、发光元件以及发光装置
EP2166001B1 (en) * 2008-09-19 2011-07-20 Semiconductor Energy Laboratory Co., Ltd. Carbazole Derivative and Method for Producing the Same
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR102844041B1 (ko) 2016-02-26 2025-08-11 가부시키가이샤 한도오따이 에네루기 켄큐쇼 유기 화합물, 발광 소자, 발광 장치, 전자 기기, 및 조명 장치
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (en) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetic spirochroman compounds
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
TWI712412B (zh) 2018-04-19 2020-12-11 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
SG11202012425QA (en) 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US12421331B2 (en) 2023-11-09 2025-09-23 Chevron Phillips Chemical Company Lp Systems and methods for chromium catalyst activation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535330A (en) * 1968-04-29 1970-10-20 Sandoz Ag 2,6-diphenyl - 4 - (p-(dilower-alkyl amino lower - alkoxy)phenyl)pyridines and derivatives thereof
US3928449A (en) * 1969-04-03 1975-12-23 Sandoz Ag Aminoalkoxy-terphenyls and the salts thereof
LU78484A1 (de) * 1977-11-10 1979-06-13 Ciba Geigy Ag Verfahren zur herstellung von benzoxazolyl-phenyl-stilbenen
DE2752361A1 (de) * 1977-11-24 1979-06-07 Troponwerke Gmbh & Co Kg Neue indolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP1218336A2 (en) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Melanin concentrating hormone antagonist

Also Published As

Publication number Publication date
WO2004052848A1 (en) 2004-06-24
US7132456B2 (en) 2006-11-07
BR0316948A (pt) 2005-10-18
EP1572637A1 (en) 2005-09-14
AU2003302925A1 (en) 2004-06-30
CN1726189A (zh) 2006-01-25
CA2509042A1 (en) 2004-06-24
US20060052449A1 (en) 2006-03-09
JP2006509801A (ja) 2006-03-23

Similar Documents

Publication Publication Date Title
MXPA05006272A (es) Novedosos antagonistas de receptores de mch.
AU749271B2 (en) Glucagon antagonists/inverse agonists
RU2673245C2 (ru) Производные 4-аминометилбензойной кислоты
KR20170048588A (ko) 바이사이클릭 화합물
JPWO2003029199A1 (ja) ベンゼン誘導体、その製造法および用途
PT2208727E (pt) Éteres diarílicos como antagonista do receptor opióide
CA2415331A1 (en) Beta3 adrenergic agonists
US20120022116A1 (en) Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
WO2003087045A1 (en) Novel methoxybenzamide compounds for use in mch receptor related disorders
WO2017007695A1 (en) Mu opioid receptor modulators
CA2542220A1 (en) Novel mch receptor antagonists
NZ523951A (en) Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors
BRPI0610119A2 (pt) compostos, uso dos compostos, composição farmacêutica, método de tratamento de uma doença, e, agente para a prevenção ou tratamento de uma doença
MXPA02005742A (es) 1,2-diaril bencimidazoles para el tratamiento de enfermedades asociadas con la activacion de la micrologia.
ES2939730T3 (es) Compuestos de heteroarilo de 5 miembros que contienen un resto hidroxamato y su uso
JP2006522012A (ja) ベンゾキサゾシンおよびそのモノアミン再吸収阻害剤としての用途
BRPI0610240A2 (pt) compostos, composição farmacêutica, uso do composto, método de tratamento de uma doença, e, processo para preparação de um composto
WO2005100301A1 (en) 2-aryloxyethyl glycine derivatives and their use as glycine transport inhibitors
AU561190B2 (en) Aromatic amines
Yamamoto et al. Identification of 1-Methyl-N-(propan-2-yl)-N-({2-[4-(trifluoromethoxy) phenyl] pyridin-4-yl} methyl)-1H-imidazole-4-carboxamide as a Potent and Orally Available Glycine Transporter 1 Inhibitor
WO2007036730A9 (en) Thiophene derivatives as ppar agonists i
KR19990038717A (ko) 3-(치환-페닐티오)-4-하이드록시퀴놀린-2(1h)-온 유도체 및 그들의 제조방법
MX2007014266A (es) Nuevos derivados de cromano o tetrahidronaftaleno 8-sulfonil-3-aminosustituidos que modulan al receptor de 5-hidroxi-triptamina 6.
JP2004339061A (ja) ベンゼン誘導体、その製造法および用途
CZ446799A3 (cs) Glukagonoví antagftiisté/inverzní agonisté